JAZZ Stock Recent News

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

The global pharmaceutical cannabis market is poised for significant growth, projected to swell by 23% by 2027, mostly from one company but with other contenders battling to enter the market. In 2023, sales of prescription drugs containing cannabis are estimated to total US$1.11 billion, according to a new report by Prohibition Partners, with sales of currently approved drugs seen expanding to US$1.37 billion.

Jazz Pharmaceuticals and Innovative Industrial Properties have been standouts in the cannabis industry. Both companies have been able to sidestep issues that plague their peers in the industry.

The consensus price target hints at a 51.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $4.51 per share, beating the Zacks Consensus Estimate of $4.46 per share. This compares to earnings of $4.30 per share a year ago.

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Jazz Pharmaceuticals' current valuation is significantly lower than the sector average, despite strong margins and a positive growth outlook, presenting a potential investment opportunity. The company is making progress in its clinical trials and is diversifying its product offerings to mitigate the impact of generic drugs entering the market. Despite some challenges, such as a lengthy regulatory approval process for a new product, Jazz Pharmaceuticals is well-positioned to achieve its target of $5 billion in revenues by 2025.